Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Olema Pharmaceuticals Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and are located in 3 distinct art units. This indicates a broad technical scope for the pending applications, as they span multiple administrative groups. Such a distribution requires the applicant to navigate 3 distinct examiners across these 3 distinct art units.
The busiest examiner, HIRAKIS, SOPHIA P, is responsible for 1 pending office action. This represents 1 of the 3 total pending office actions. With 3 distinct examiners and 3 distinct art units, each of the 3 pending office actions is being examined in a unique environment. This structure suggests that the company's current filings in Biotechnology & Pharmaceuticals are diverse enough to require separate technical reviews. The presence of 1 pending action under the busiest examiner reflects a balanced workload across the 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142068 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | RODRIGUEZ, RAYNA B | 62d |
| 18576880 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | HIRAKIS, SOPHIA P | — |
| 17908941 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | BAUER, NICOLA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1628 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576880 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18142068 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | RODRIGUEZ, RAYNA B | 1628 | DPOther | Non-Final OA | 62d | Pending | May 02, 2023 |
| 17908941 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | BAUER, NICOLA MARIA | 1621 | §103DP | Non-Final OA | — | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial